Published in Women's Health Law Weekly, September 25th, 2005
In addition, the adjuvant therapy for the prevention of recurrence after the surgical operation of premenopausal breast cancer was approved for this injection kit 11.25, and also for Leuplin for injection 3.75 and Leuplin for injection kit 3.75, both of which were already approved for the indication of premenopausal breast cancer.
The dosage and administration of Leuplin SR for injection...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly